Literature DB >> 31420815

Raynaud's phenomenon-an update on diagnosis, classification and management.

John D Pauling1,2, Michael Hughes3, Janet E Pope4.   

Abstract

Raynaud's phenomenon (RP) is used to describe a symptom complex caused by digital vascular compromise. RP is a clinical diagnosis. The typically episodic nature of RP has resulted in a reliance upon patient self-report for diagnosis. The term 'primary RP' is generally applied when no underlying pathology can be demonstrated. Whilst 'primary RP' is currently considered a distinct disorder, there is evidence that the term may comprise several entities that include a functional vasospastic disorder, a physiologically appropriate thermoregulatory response, subclinical atherosclerosis and 'cold intolerance'. Optimal management may differ depending on cause. The term 'secondary RP' encompasses a broad range of rheumatological, haematological, endocrinological and vascular pathology. RP can range from relatively benign but intrusive vasospasm, to the progressive obliterative microangiopathy of systemic sclerosis (SSc), in which severe digital ischaemia can threaten tissue viability. SSc has formed the focus of much of the research into RP but, consistent with most medical symptom complexes, the aetiopathogenesis of RP varies greatly dependent on cause. Vasospasm within the digital macro- and microvasculature occurs in SSc, but digital ischaemia is further compounded by a progressive obliterative microangiopathy. Recent work exploring the patient experience of SSc-RP is challenging the 'episodic' paradigm of 'Raynaud's', with important implications for clinical trials utilising diary-based patient-reported outcome instruments for assessing Raynaud's symptoms. This review shall examine the causes, pathogenesis, clinical features, classification and management of RP. A practical approach to the evaluation and management of RP is outlined, highlighting important knowledge gaps and unmet research needs where applicable. Key Points • Raynaud's phenomenon is a symptom complex related to digital vascular compromise secondary to broad-ranging pathology. • Raynaud's phenomenon, as currently classified, likely encompasses a number of aetiopathogenic processes. • Raynaud's phenomenon causes significant disease-related morbidity in autoimmune rheumatic diseases such as systemic sclerosis.

Entities:  

Keywords:  Assessment; Classification; Management; Pathogenesis; Raynaud’s phenomenon; Systemic sclerosis

Mesh:

Year:  2019        PMID: 31420815     DOI: 10.1007/s10067-019-04745-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?

Authors:  Michael Hughes; Dinesh Khanna; John D Pauling
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

2.  Raynaud's phenomenon and blood rheology: comments on the article "Raynaud's phenomenon-an update on diagnosis, classification and management".

Authors:  Edward S Harris
Journal:  Clin Rheumatol       Date:  2019-10-22       Impact factor: 2.980

Review 3.  Testicular cancer survivorship: Long-term toxicity and management.

Authors:  Noa Shani Shrem; Lori Wood; Robert J Hamilton; Kopika Kuhathaas; Piotr Czaykowski; Matthew Roberts; Andrew Matthew; Jason P Izard; Peter Chung; Lucia Nappi; Jennifer Jones; Denis Soulières; Armen Aprikian; Nicholas Power; Christina Canil
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

Review 4.  A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Silvia Piantoni; Fabrizio Angeli; Stefania Bertocchi; Franco Franceschini; Paolo Airò
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-07       Impact factor: 10.817

5.  Is there any Sympathetic Skin Response Abnormality in Raynaud Phenomenon?

Authors:  Mohammad R Emad; Hamid R Farpour; Faisal Ahmed; Masoumeh Tayebi; Mohammadali Nazarinia; Mohammad R Askarpour; Hossein-Ali Nikbakht
Journal:  Sultan Qaboos Univ Med J       Date:  2022-05-26

Review 6.  Raynaud phenomenon and digital ulcers in systemic sclerosis.

Authors:  Michael Hughes; Yannick Allanore; Lorinda Chung; John D Pauling; Christopher P Denton; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2020-02-25       Impact factor: 20.543

7.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

Review 8.  Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.

Authors:  Iqra Nawaz; Yashfa Nawaz; Eisha Nawaz; Muhammad Romail Manan; Adil Mahmood
Journal:  Cureus       Date:  2022-01-28

Review 9.  Management of systemic sclerosis: the first five years.

Authors:  David Roofeh; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

10.  Clinical features and risk factors of Raynaud's phenomenon in primary Sjögren's syndrome.

Authors:  Wei Lin; Zhifei Xin; Xiaoran Ning; Yang Li; Xiuying Ren; Yashuang Su; Meilu Liu; Shaoying Guo; Liu Yang; Yixuan Liu; Fengxiao Zhang; Wen Zhang
Journal:  Clin Rheumatol       Date:  2021-04-29       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.